Tuesday, December 01, 2020 11:58:57 AM
From that
Traf2 inhibitors for use in the treatment of a cancer
Application filed by Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis
The siRNA, shRNA, miRNA, plasmid expressing the shRNA, plasmid expressing the siRNA, or plasmid expressing the miRNA (or miRNA precursor), can be coupled to a carrier suitable for delivery into the cell. A preferred carrier is selected from the group consisting of a lipoplex, a liposome, a polymersome, a polyplex, a dendrimer, an inorganic nanoparticle, a virosome and cell- penetrating peptides.
https://patents.google.com/patent/WO2020002592A1/en
T cell manufacturing compositions and methods
Stichting Het Nederlands Kanker Instituut
PepTel® vector system, PLG microparticles, resiquimod, SRL172, virosomes and other virus-like particles, YF-17D, VEGF trap, R848, ß-glucan, Pam3Cys, Pam3CSK4, Aquila's QS21 stimulon (Aquila Biotech, Worcester, Mass., USA) which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox.
https://patents.google.com/patent/WO2019094642A1/en
Groningen
Laboratory of Molecular Virology, State University of Groningen
Before his appointment in 1999 at the Laboratory of Molecular Virology, J.C.
Wilschut was affiliated to the Laboratory of Physiological Chemistry of the
University of Groningen. He investigated model systems of fusion processes
between endosomal cellular membranes and reconstituted viral envelope
membranes (virosomes) after internalization through receptor-mediated
endocytosis. The virosomes can be used for intracellular delivery of antigens
for the induction of immune responses as well as drugs for treatment of
tumours. The majority of the studies on such applications were executed
after the turn of the century together with his co-workers C.A.H.H. Daemen
and A. Huckriede, who were both appointed professor in 2008 and 2011,
respectively. The clinical part of their studies was carried out in collaboration
with clinicians as A.G. van der Zee of the Department of Gynaecology.
https://library.oapen.org/bitstream/handle/20.500.12657/22972/9789048544066.pdf?sequence=1&isAllowed=y
Traf2 inhibitors for use in the treatment of a cancer
Application filed by Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis
The siRNA, shRNA, miRNA, plasmid expressing the shRNA, plasmid expressing the siRNA, or plasmid expressing the miRNA (or miRNA precursor), can be coupled to a carrier suitable for delivery into the cell. A preferred carrier is selected from the group consisting of a lipoplex, a liposome, a polymersome, a polyplex, a dendrimer, an inorganic nanoparticle, a virosome and cell- penetrating peptides.
https://patents.google.com/patent/WO2020002592A1/en
T cell manufacturing compositions and methods
Stichting Het Nederlands Kanker Instituut
PepTel® vector system, PLG microparticles, resiquimod, SRL172, virosomes and other virus-like particles, YF-17D, VEGF trap, R848, ß-glucan, Pam3Cys, Pam3CSK4, Aquila's QS21 stimulon (Aquila Biotech, Worcester, Mass., USA) which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox.
https://patents.google.com/patent/WO2019094642A1/en
Groningen
Laboratory of Molecular Virology, State University of Groningen
Before his appointment in 1999 at the Laboratory of Molecular Virology, J.C.
Wilschut was affiliated to the Laboratory of Physiological Chemistry of the
University of Groningen. He investigated model systems of fusion processes
between endosomal cellular membranes and reconstituted viral envelope
membranes (virosomes) after internalization through receptor-mediated
endocytosis. The virosomes can be used for intracellular delivery of antigens
for the induction of immune responses as well as drugs for treatment of
tumours. The majority of the studies on such applications were executed
after the turn of the century together with his co-workers C.A.H.H. Daemen
and A. Huckriede, who were both appointed professor in 2008 and 2011,
respectively. The clinical part of their studies was carried out in collaboration
with clinicians as A.G. van der Zee of the Department of Gynaecology.
https://library.oapen.org/bitstream/handle/20.500.12657/22972/9789048544066.pdf?sequence=1&isAllowed=y
